Editors' ChoiceCancer

Early stage EGFR-mutated lung cancer gets a targeted treatment

See allHide authors and affiliations

Science Translational Medicine  28 Oct 2020:
Vol. 12, Issue 567, eabf2637
DOI: 10.1126/scitranslmed.abf2637

Abstract

Osimertinib improves disease-free survival for patients with early stage EGFR-mutated non-small cell lung cancer after complete tumor resection.

View Full Text

Stay Connected to Science Translational Medicine